pembrolizumab (Keytruda) for advanced melanoma in ipilimumab naïve patients -

pembrolizumab (Keytruda) for advanced melanoma in ipilimumab naïve patients
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Cancers | Skin disorders
Summary
The SMC has accepted for use in NHS Scotland, pembrolizumab (Keytruda) as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab. The advice takes account of a PAS that improves the cost-effectiveness.
UKMi comment
Separately, DRAFT NICE guidance also recommends pembrolizumab as a treatment option in this setting, providing the company provides pembrolizumab with the discount agreed in the patient access scheme (PAS).
Related links: NICE guidance